Advertisement

Different manifestations of patients with inhibitors against prothrombin and thrombin

  • 24 Accesses

This is a preview of subscription content, log in to check access.

Access options

Buy single article

Instant unlimited access to the full article PDF.

US$ 39.95

Price includes VAT for USA

Subscribe to journal

Immediate online access to all issues from 2019. Subscription will auto renew annually.

US$ 99

This is the net price. Taxes to be calculated in checkout.

References

  1. 1.

    Mann KG, Nesheim ME, Church WR, Haley P, Krishnaswamy S (1990) Surface-dependent reactions of the vitamin K-dependent enzyme complexes. Blood 76(1):1–16

  2. 2.

    Rabiet MJ, Furie BC, Furie B (1986) Molecular defect of prothrombin Barcelona: substitution of cysteine for arginine at residue 273. J Biol Chem 261(32):15045–15048

  3. 3.

    Colwell NS, Tollefsen DM, Blinder MA (1997) Identification of a monoclonal thrombin inhibitor associated with multiple myeloma and a severe bleeding disorder. Br J Haematol 97(1):219–226

  4. 4.

    Sciascia S, Khamashta MA, Bertolaccini ML (2014) New tests to detect antiphospholipid antibodies: antiprothrombin (aPT) and anti-phosphatidylserine/prothrombin (aPS/PT) antibodies. Curr Rheumatol Rep 16(5):415

  5. 5.

    Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R et al (2006) International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 4(2):295–306

  6. 6.

    Bertolaccini ML, Atsumi T, Koike T, Hughes GR, Khamashta MA (2005) Antiprothrombin antibodies detected in two different assay systems. Prevalence and clinical significance in systemic lupus erythematosus. Thromb Haemost 93(2):289–297

  7. 7.

    Atsumi T, Ieko M, Bertolaccini ML, Ichikawa K, Tsutsumi A, Matsuura E et al (2000) Association of autoantibodies against the phosphatidylserine-prothrombin complex with manifestations of the antiphospholipid syndrome and with the presence of lupus anticoagulant. Arthritis Rheum 43(9):1982–1993

  8. 8.

    Bajaj SP, Rapaport SI, Fierer DS, Herbst KD, Schwartz DB (1983) A mechanism for the hypoprothrombinemia of the acquired hypoprothrombinemia-lupus anticoagulant syndrome. Blood 61(4):684–692

  9. 9.

    Rapaport SI, Ames SB, Duvall BJ (1960) A plasma coagulation defect in systemic lupus erythematosus arising from hypoprothrombinemia combined with antiprothrombinase activity. Blood 15:212–227

  10. 10.

    Sciascia S, Sanna G, Murru V, Roccatello D, Khamashta MA, Bertolaccini ML (2013) Anti-prothrombin (aPT) and antiphosphatidylserine/prothrombin (aPS/PT) antibodies and the risk of thrombosis in the antiphospholipid syndrome. A systematic review. Thromb Haemost 111(2):354–364

  11. 11.

    Coppola A, Tufano A, Di Capua M, Franchini M (2011) Bleeding and thrombosis in multiple myeloma and related plasma cell disorders. Semin Thromb Hemost 37(8):929–945

  12. 12.

    Tang N, Yu F, Cao W, Li D (2019) Significantly prolonged PT and APTT could indicate a wide spectrum of clinical manifestations in three patients with plasma cell disorders. Int J Lab Hematol 41(1):e23–e26

  13. 13.

    Eby C (2009) Pathogenesis and management of bleeding and thrombosis in plasma cell dyscrasias. Br J Haematol 145(2):151–163

Download references

Author information

Correspondence to Dengju Li.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Tang, N., Li, D. Different manifestations of patients with inhibitors against prothrombin and thrombin. J Thromb Thrombolysis 49, 164–167 (2020) doi:10.1007/s11239-019-01948-0

Download citation